|
C1ORF74 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.28501678584325E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.01723140600552E-13 |
| Normal-vs-Stage2 |
2.35270025683576E-10 |
| Normal-vs-Stage3 |
2.242600E-04 |
| Normal-vs-Stage4 |
2.93165491882519E-12 |
| Stage1-vs-Stage2 |
6.416800E-01 |
| Stage1-vs-Stage3 |
3.474000E-01 |
| Stage1-vs-Stage4 |
1.277980E-01 |
| Stage2-vs-Stage3 |
5.021000E-01 |
| Stage2-vs-Stage4 |
1.567220E-01 |
| Stage3-vs-Stage4 |
1.317840E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.73530120565147E-11 |
| Normal-vs-AfricanAmerican |
1.80080000022897E-07 |
| Normal-vs-Asian |
1.26450000470513E-08 |
| Caucasian-vs-AfricanAmerican |
5.930800E-01 |
| Caucasian-vs-Asian |
8.183600E-01 |
| AfricanAmerican-vs-Asian |
5.315200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.10689235555128E-13 |
| Normal-vs-Female |
1.25119914429206E-11 |
| Male-vs-Female |
8.734800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.2775119264179E-13 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
3.226300E-04 |
| Normal-vs-Age(81-100Yrs) |
3.556700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.557000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.882200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.983600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.027200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.127200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.500800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.615600E-01 |
| Classical-VS-Follicular |
4.350000E-02 |
| Classical-VS-Other |
1.536550E-01 |
| Classical-VS-Normal |
2.67420530164486E-11 |
| Tall-VS-Follicular |
3.280600E-01 |
| Tall-VS-Other |
2.028200E-01 |
| Tall-VS-Normal |
3.503200E-01 |
| Follicular-VS-Other |
3.077000E-01 |
| Follicular-VS-Normal |
4.33542091116124E-13 |
| Other-VS-Normal |
8.19050000000487E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.49764703048095E-13 |
| Normal-vs-N1 |
5.75095526755831E-14 |
| N0-vs-N1 |
5.421700E-02 |
|
|
